The cancer and leukemia group B transplant committee.
The Transplant Committee of the Cancer and Leukemia Group B has a robust portfolio of studies and is poised to make significant contributions to the field. We are working in collaboration with the Cancer and Leukemia Group B Leukemia and Lymphoma Disease Committees and importantly in collaboration with other groups to define the role of both autologous and reduced-intensity allogeneic transplantation in the management of selected hematologic malignancies. Some of our studies have the potential to change the standard of care in areas such as the maintenance therapy for multiple myeloma after autologous transplantation and to generate the data that could lead to acceptance of new approaches to the initial post-remission therapy of older adults with acute myeloid leukemia. The cooperative group setting allows us to advance the transplant field by showing which approaches are successful outside of single institutions and are therefore feasible on a generalized basis.
Linker
Charles
C
University of California at San Francisco, San Francisco, California and Wake Forest, Winston-Salem, North Carolina, USA. linkerc@medicine.ucsf.edu
Hurd
David
D
D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007938:Leukemia / Q000628:therapy; D008297:Male; D009369:Neoplasms / Q000628:therapy*; D012107:Research Design; D012955:Societies, Medical; D014180:Transplantation / Q000639:trends